JCM
REGN icon

JD Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

JD Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,347
Closed -$11M – 23
2017
Q2 		$11M Buy
22,347
+8,004
+56% +$3.5M 2.65% 15
2017
Q1 		$5.56M Buy
+14,343
New +$5.32M 1.8% 10

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JD Capital Management's REGN Position: Q3 2017 in Review

JD Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 22,347 shares — an estimated $11M sold.

JD Capital Management first reported a position in REGN in Q1 2017 and held it in 2 quarters. The position peaked at $11M in Q2 2017. 605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

  • JD Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • JD Capital Management sold 22,347 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $11M.
  • JD Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • JD Capital Management's Regeneron Pharmaceuticals position peaked at $11M in Q2 2017.
  • 605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on JD Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.